PubMed · 11436373
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
2001-06-25. The replacements.. https://pubmed.ncbi.nlm.nih.gov/11436373/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
This paper describes the use of a microsphere sensor technology that allows simple fabrication of vapor sensor arrays with reproducible response patterns. Microsphere sensor fabrication protocols are uncomplicated and yield billions of highly reproducible sensors. Microsphere sensor arrays combined with a generalized Whitney-Mann-Wilcoxen (GWMW) classifier were used to discriminate between the presence and absence of nitroaromatic compounds in high background vapor mixtures. The classifier was trained on one sensor array and then used to obtain 98.2 and 93.7% correct classification rates with data collected using two subsequent arrays made up to six months after the initial training was performed. These results represent an advance in the ability to transfer training data between multiple sensor arrays with a fluorescence-based artificial nose.
In our department, two spinal cord lesion patients suffering from neurogenic bladder dysfunction were selected for the implantation of a Brindley stimulator, as they could not be managed by conservative treatment. Accurate positioning of the external transmitter block over the subcutaneous receiver block, which is essential for the Brindley stimulator to function correctly, posed problems for the relatives who had to apply the external transmitter. In order to facilitate positioning, dermatography was used to mark the exact spot where the external transmitter should be placed. A 3-year follow-up showed that this marking solved the problem completely and that recurrent urinary tract infections stopped.
Cell engineering technology using recombinant microorganisms has created new opportunities in the development of innovative drugs. This article presents the use of living genetically engineered microorganisms, such as bacteria or yeasts, as a new delivery vehicle to the gastrointestinal tract. This 'biodrug' concept was demonstrated using recombinant Saccharomyces cerevisiae expressing the plant cytochrome P450 73A1. This enzyme provides a relevant model for potential therapeutic applications, such as 'biodetoxication' in the digestive environment. An artificial gastrointestinal tract simulating human digestion was chosen as a powerful tool to validate the biodrug concept. This approach offers a novel strategy for drug discovery and testing.